Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Acts as a negative regulator of innate and adaptive immunity by maintaining immune homeostasis. Zusätzlich bieten wir Ihnen Tumor Necrosis Factor, alpha-Induced Protein 8-Like 2 Proteine (11) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 55 products:
Human Polyclonal TNFAIP8L2 Primary Antibody für EIA, WB - ABIN955273
Zhang, Hao, Lou, Xi, Wang, Wang, Qu, Guo, Chen, Zhang, Liu: Tissue-specific expression of TIPE2 provides insights into its function. in Molecular immunology 2010
Human Polyclonal TNFAIP8L2 Primary Antibody für ELISA, WB - ABIN1450851
Sun, Gong, Carmody, Hilliard, Li, Sun, Kong, Xu, Hilliard, Hu, Shen, Yang, Chen: TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. in Cell 2008
the expression of TIPE2 protein could be a predictor of better prognosis for DLBCL.
Insufficient expression of TIPE2 might be involved in the hyperreactivity of monocyte to Toll (zeige TLR4 Antikörper)-like receptor ligands in primary biliary cirrhosis.
data provided the first evidence that TIPE2 inhibits gastric cancer cell migration, invasion and metastasis very probably via reversal of EMT (zeige ITK Antikörper), revealing that TIPE2 may be a novel therapeutic target for human gastric cancer EMT (zeige ITK Antikörper) and metastasis.
Authors demonstrated that TIPE2 overexpression may suppress proliferation, migration, and invasion in prostate cancer cells by inhibiting the PI3K (zeige PIK3CA Antikörper)/Akt (zeige AKT1 Antikörper) signaling pathway.
TIPE2 suppressed breast cancer tumorigenesis, growth and metastasis possibly via regulation of the AKT (zeige AKT1 Antikörper) and p38 (zeige CRK Antikörper) signaling pathways.
these data suggest that TIPE2 overexpression inhibited hypoxia-induced Wnt (zeige WNT2 Antikörper)/beta-catenin (zeige CTNNB1 Antikörper) pathway activation and EMT (zeige ITK Antikörper) in glioma cells.
this study shows that TIPE2 contributes to the pathogenesis of ankylosing spondylitis
TIPE2 expression was significantly decreased in human breast cancer tissue and cell lines. Overexpression of TIPE2 inhibited the proliferation in vitro and tumor xenograft growth in vivo. TIPE2 also inhibited the migration/invasion of breast cancer cells through preventing the epithelial-to-mesenchymal transition (EMT (zeige ITK Antikörper)) phenotype.
Low expression of TIPE2 is associated with hepatocellular carcinogenesis.
our data suggest a previously unappreciated role of TIPE2 in the crosstalk between skin SCC (zeige CYP11A1 Antikörper) and TAMs and highlight TIPE2 as a promising novel target for skin SCC (zeige CYP11A1 Antikörper) treatment.
TIPE2 inhibited breast cancer development and metastasis possibly via promoting CD8 (zeige CD8A Antikörper)(+) T and NK cell-mediated antitumor immune responses
Our current study shows that TIPE2-deficient bone-marrow cells are defective in IL-4 (zeige IL4 Antikörper) induced M2 macrophage differentiation in vitro. TIPE2 promotes phosphoinositide metabolism and the activation of the down-stream AKT (zeige AKT1 Antikörper) signaling pathway, which in turn leads to the expression of markers specific for M2 macrophages.
The present study demonstrates that TIPE2 acts as a novel negative regulator of inflammatory and immune responses through TAK1 (zeige NR2C2 Antikörper) signaling.
Data show that after tumor necrosis factor alpha-induced protein 8 like-2 (TIPE2) gene was down-regulated, the expression of the CD69 antigen (zeige CD69 Antikörper) was increased, and the proliferation of T lymphocytes and the secretion of cytokines IL-2 (zeige IL2 Antikörper) and IFN-gamma (zeige IFNG Antikörper) were enhanced.
TIPE2 alleviates experimental SLE through induction of macrophage polarization to a M2 phenotype, which may be used as a promising therapeutic strategy for treating SLE.
TIPE2 acts as a negative regulator linking NOD2 (zeige NOD2 Antikörper) and inflammatory responses.
TIPE2 plays a suppressive role in injury-induced restenosis and may serve as a new therapeutic target for treating the disease.
Tipe2 provides a molecular bridge between miR (zeige MLXIP Antikörper)-21 and cell apoptosis; miR (zeige MLXIP Antikörper)-21 suppresses apoptosis in activated T cells at least in part through directly targeting tumor suppressor gene Tipe2.
TIPE2 deficiency in hematopoietic cells ameliorates experimental colitis; TIPE2 is a negative regulator of antibacterial immunity, indicating that TIPE2 promotes colitis by inhibiting mucosal immunity to commensal bacteria.
TIPE2 plays a crucial atheroprotective role likely by regulating macrophage responses to oxidized low-density lipoprotein.
Acts as a negative regulator of innate and adaptive immunity by maintaining immune homeostasis. Negative regulator of Toll-like receptor and T-cell receptor function. Prevents hyperresponsiveness of the immune system and maintains immune homeostasis. Inhibits jun/ap1 and NF-kappa-B activation. Promotes Fas-induced apoptosis (By similarity).
TNF alpha-induced protein 8-like protein 2
, TNFAIP8-like protein 2
, inflammation factor 20
, inflammation factor protein 20
, tumor necrosis factor alpha-induced protein 8-like protein 2
, tumor necrosis factor, alpha-induced protein 8-like protein 2
, Tumor necrosis factor, alpha-induced protein 8-like protein 2
, tumor necrosis factor, alpha-induced protein 8-like protein 2 a